Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Touts Benefit Of Health Economic Data For Targeted Cancer Therapies

This article was originally published in The Pink Sheet Daily

Executive Summary

Reimbursement for Genentech's Avastin indicates the value of health economic data, Roche Worldwide Pharmaceuticals Head William Burns said

You may also be interested in...

CMS’ Off-Label Coverage Decision For Colorectal Cancer Drugs Could Include Registries

The Centers for Medicare & Medicaid Services’ national coverage determination for oncologics, including Avastin and Erbitux, could be modeled on coverage for PET scans in Alzheimer’s patients, which includes trial registries. CMS expects to complete its coverage determination by Dec. 31.

Avastin Account Orders Double, Reorder Rate Improves To 80%

The number of accounts ordering the oncologic rose from 1,500 to more than 3,000 in the second quarter, with 80% of accounts placing reorders. Genentech says the majority of Avastin's sales come from the front-line setting.

Colorectal Cancer Drug Costs May Force Rationing – ASCO Presentation

Cost per patient has soared from $500 to $250,000 in past decade, Memorial-Sloan Kettering Research says. It would cost $7.5 bil. to treat all colorectal cancer patients unless some restraints are put in place.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts